Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor ...
These high attrition rates compared with those of other therapeutic areas can be explained in part by particular characteristics of oncology drugs, 4 including a narrow therapeutic index, complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results